JSR Invites AuB Co., Ltd. to Kawasaki Collaborative Research Facility, JSR BiRD, Challenging Value Creation in the Microbiome
Tokyo, Japan, June 6, 2022 - JSR Corporation (Head Office: Minato-ku, Tokyo, Representative Director and CEO: Eric Johnson, JSR Corporation) announced today that it has entered into a facility usage agreement with AuB Co., Ltd. (AuB), a company engaged in the study of intestinal microbiota in athletes, for the Collaborative Lab, a collaborative research facility with startups, which is located in a new research laboratory "JSR Bioscience and Informatics R & D center (JSR BiRD)" in Kawasaki City, Kanagawa Prefecture, which opened last July.
AuB, founded in Oct 2015, is a company that conducts food-tech business based on research into the intestinal bacteria of athletes. Representative director Keita Suzuki is a former top athlete who was a professional player for the Urawa Red Diamonds, a J.League soccer team, and also played for Japan's national team. Since its foundation, the company has analyzed the intestinal environment of more than 750 athletes (1,700 samples), developed proprietary materials based on this knowledge, and developed a business to sell them externally. In the future, the company is also considering entering the pharmaceutical field.
JSR is developing its life science business as a core business, focusing on diagnostic reagent materials, bioprocess materials, and drug discovery support businesses. At the same time, JSR is engaged in research on the microbiome, etc. as next-generation technology research, and is pursuing the realization of innovation that leads to new products and services required for a healthy and long-lasting society. Through joint research with AuB in collaboration labs, we aim to further accelerate next generation research and commercialize it.
Joint research Kagawa University, Shigakukan University, etc. Location: Ginza 7 -13 -6, Chuo-ku, Tokyo
Phone 03-4455-2139HP https://aub.co.jp/
Contact details
-
- Missy Bindseil
-
JSR Life Sciences Company Inquiries
Director, Marketing & Communications - mbindseil@jsr-nahq.com
Related topics
Related news
JSR Life Sciences to Launch Amsphere™ A+, a Next-Generation Protein A Resin for Antibody Drug Purification
Amsphere™ A+ enhances antibody drug production with advanced polymer technology and high binding capacity, debuting at BPI 2024 and BioJapan.
JSR Active Innovation Fund LLC invests in Aillis, Inc., which develops and sells AI medical devices
JSR-AIF participated in the Series D financing of Aillis for the purpose of raising funds to accelerate research and development of AI medical devices, sales, and marketing promotion
JSR Begins Development of Raw Materials from Biomass
Through joint development with Bacchus Bio innovation, JSR will develop and produce raw materials for its key biomass products utilizing synthetic biology.
Ajinomoto Co., Inc. and JSR Corporation Agree to Collaborate in Development of Global Biopharmaceutical Culture Media...
Ajinomoto Co. has reached an agreement with JSR to collaborate on the global expansion of its biopharmaceutical culture media business, adding new high-performance media developed by JSR, to Ajinom...